Earnings call transcript: Ipsen lifts 2026 outlook after strong Q3 growth
Ipsen reported a 26.7% increase in third-quarter sales to 1.1 billion euros, while year-to-date sales grew by 24.6% to 3.364 billion euros. The French drugmaker raised its full-year 2026 outlook and increased its core operating margin guidance to around 39%. Ipsen's shares were slightly up in early trading, reaching $152.3, near the middle of its 52-week range.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
